U.S. Markets close in 6 hrs 21 mins

Atossa Genetics Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.54690+0.02690 (+5.17308%)
As of 9:38AM EDT. Market open.
People also watch
BIOCAPRIHTBXAVEOSGNL

Atossa Genetics Inc.

107 Spring Street
Seattle, WA 98104
United States
206-588-0256
http://www.atossagenetics.com

SectorHealthcare
IndustryDiagnostic Substances
Full Time Employees4

Key Executives

NameTitlePayExercisedAge
Dr. Steven C. Quay M.D., Ph.D., FCAPChairman, Chief Exec. Officer, Pres and Treasurer830.6kN/A66
Mr. Kyle Guse Esq., CPAChief Financial Officer, Gen. Counsel and Sec.544.6kN/A53
Mr. Pieter Van Der PoelVP of European Commercial OperationsN/AN/A54
Ms. Janet Rose Rea MSPH, RACVP of Regulatory Affairs & QualityN/AN/AN/A
Dr. Jack Cuzick Ph.D., FRS, FMedSci, FRCP (hon)Scientific AdvisorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Corporate Governance

Atossa Genetics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.